When.com Web Search

  1. Ads

    related to: positive a cologuard test results take to come back after chemo infusion

Search results

  1. Results From The WOW.Com Content Network
  2. Some Cologuard users hit with unexpected high bills after ...

    www.aol.com/news/cologuard-users-hit-unexpected...

    For premium support please call: 800-290-4726 more ways to reach us

  3. FDA Clears Exact Sciences' Next-Generation Colorectal Cancer ...

    www.aol.com/finance/fda-clears-exact-sciences...

    The Cologuard Plus test is now approved for adults ages 45 and older who are at average risk for colorectal cancer (CRC). FDA approval was based on findings from the pivotal BLUE-C study, one of ...

  4. Top-Line Data Show Exact Sciences' Cologuard Test ...

    www.aol.com/news/2013-04-18-top-line-data-show...

    Sensitivity measures a test's ability to correctly identify positive results. It is the percentage of patients who were determined by colonoscopy to have pre-cancerous polyps or cancer who had a ...

  5. Colonoscopy - Wikipedia

    en.wikipedia.org/wiki/Colonoscopy

    A positive test is almost always an indication to do a colonoscopy. In most cases the positive result is just due to hemorrhoids ; however, it can also be due to diverticulosis , inflammatory bowel disease ( Crohn's disease , ulcerative colitis ), colon cancer, or polyps .

  6. FOLFOX - Wikipedia

    en.wikipedia.org/wiki/FOLFOX

    The dose schedule given every two weeks is as follows: [5] Day 1–2: Oxaliplatin 100 mg/m 2 IV infusion, given as a 120 minutes IV infusion in 500 mL D5W, concurrent with leucovorin 400 mg/m 2 (or levoleucovorin 200 mg/m 2) IV infusion, followed by 5-FU 400 mg/m 2 IV bolus, followed by 46-hour 5-FU infusion (2400 mg/m 2 for first two cycles, and may be increased to 3000 mg/m 2 if tolerated by ...

  7. Exact Sciences Corp. - Wikipedia

    en.wikipedia.org/wiki/Exact_Sciences_Corp.

    Exact Sciences Corp. is an American molecular diagnostics company based in Madison, Wisconsin specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer; in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer.